Kelly Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Kelly Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-74	Closed	-$34.7K	–	739
2024 Q2	$34.7K	Hold	74	–	–	0.01%	267
2024 Q1	$30.9K	Hold	74	–	–	0.01%	274
2023 Q4	$30.1K	Hold	74	–	–	0.01%	262
2023 Q3	$25.7K	Hold	74	–	–	0.01%	254
2023 Q2	$26K	Hold	74	–	–	0.01%	261
2023 Q1	$23.3K	Hold	74	–	–	0.01%	263
2022 Q4	$21.4K	Hold	74	–	–	0.01%	261
2022 Q3	$21.4K	Buy	74 +2	+3%	+$575	0.01%	252
2022 Q2	$20.3K	Hold	72	–	–	0.01%	253
2022 Q1	$18.8K	Hold	72	–	–	0.01%	276
2021 Q4	$15.8K	Hold	72	–	–	0.01%	292
2021 Q3	$13.1K	Hold	72	–	–	0.01%	298
2021 Q2	$14.5K	Hold	72	–	–	0.01%	298
2021 Q1	$15.5K	Hold	72	–	–	0.01%	249
2020 Q4	$17K	Hold	72	–	–	0.01%	213
2020 Q3	$19.6K	Hold	72	–	–	0.01%	175
2020 Q2	$20.9K	Hold	72	–	–	0.02%	155
2020 Q1	$17.1K	Hold	72	–	–	0.02%	151
2019 Q4	$15.8K	Hold	72	–	–	0.01%	189
2019 Q3	$12.2K	Buy	72 +6	+9%	+$1.06K	0.01%	204
2019 Q2	$12.1K	Hold	66	–	–	0.01%	200
2019 Q1	$12.1K	Buy	+66	New	+$12.2K	0.01%	201

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Kelly Financial Services's VRTX Position: Q3 2024 in Review

Kelly Financial Services sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 74 shares — an estimated $34.7K sold.

Kelly Financial Services first reported a position in VRTX in Q1 2019 and held it in 22 quarters. The position peaked at $34.7K in Q2 2024. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

Kelly Financial Services reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Kelly Financial Services sold 74 Vertex Pharmaceuticals shares in Q3 2024, an estimated $34.7K.
Kelly Financial Services first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 22 quarters.
Kelly Financial Services's Vertex Pharmaceuticals position peaked at $34.7K in Q2 2024.
1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Kelly Financial Services's 13F filing for Q3 2024, filed 9 Oct 2024.